William Blair initiated coverage of Alcon (ALC) with a Market Perform rating and no price target Alcon is a multinational eye care company that operates through two core segments, surgical and vision care, the analyst tells investors in a research note. The firm believes the shares warrant premium is warranted valuation given the company’s “full pipeline,” but with the stock already trading at a 25% premium, its look for potential upside drivers to estimates before recommending the name.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALC:
- Alcon price target lowered to CHF 85 from CHF 90 at Berenberg
- Alcon upgraded to Buy from Hold at Deutsche Bank
- Seagate upgraded, Tractor Supply downgraded: Wall Street’s top analyst calls
- Alcon downgraded to Hold from Buy at Stifel
- Alcon Walks Away From STAAR Surgical Deal, Reaffirms Refractive Strategy